Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19Medicine Published on 2021-11-082022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 28-day mortality 95% CI addition adjusted hazard ratio Admissions anti-inflammatory activity Antiviral association Baricitinib benefit cohort study Coinfection Combination Corticosteroid Corticosteroids COVID-19 events group Hospitalization hospitalizations hospitalized patient identify Impact IMV Including increased risk inhibitor Invasive mechanical ventilation Jak Janus kinase microbiologically Mortality not different outcome Patient patients with COVID-19 Primary outcome progression Propensity score reduce mortality Remdesivir Safety SARS-CoV-2 secondary Secondary infection significant effect Standard Standard of care therapy Thromboembolic event Thromboembolic events thrombosis Tocilizumab Trial was used with COVID-19 [DOI] 10.3389/fmed.2021.749657 PMC 바로가기 [Article Type] Medicine
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination백신 접종 후 최대 5개월까지 면역 매개 염증성 질환에 걸린 환자에서 BNT162b2 mRNA COVID-19 백신에 대한 항체 반응 평가Original Article Published on 2021-11-052022-09-12 Journal: Clinical and experimental medicine [Category] MERS, SARS, 진단, [키워드] affected age anti-CD20 Antibody Response Autoimmune disease biological drug BNT162b2 BNT162b2 mRNA booster dose control group correlation Corticosteroid COVID-19 COVID-19 vaccine demographic drugs elicited enrolled Factor HCW healthcare worker healthy healthy subject humoral immune response IgG IMID Immune-mediated inflammatory disease immunogenicity immunosuppressants magnitude mRNA mRNA BNT162b2 naïve no significant difference participant Patient proportion reduced reduction SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination serum IgG significantly significantly lower statistically significant difference supplementary material the disease treated Treatment trials vaccination were recorded [DOI] 10.1007/s10238-021-00771-3 PMC 바로가기 [Article Type] Original Article
Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extentReview Published on 2021-11-042022-10-28 Journal: Beni-Suef University Journal of Basic and Applied Sciences [Category] COVID-19, [키워드] Activation age Anti-inflammatory Bacterial infections breastfeeding women can be used chemokine children clinically Combination Corticosteroid corticosteroid therapy Corticosteroids COVID-19 COVID-19 patient COVID-19 patients death Dexamethasone dosage Efficacy Evidence forms global pandemic Hospitalized Hydrocortisone hypokalemia immune cells immune response immunosuppressive effect macrophages management mechanism Medicine MERS-CoV infection Methylprednisolone moderate monocyte Mucormycosis Occurrence patients Prednisone Pregnancy Proinflammatory cytokine recorded reduce reducing Research SARS-CoV SARS-CoV-2 pandemic SARS-CoV-2 patient Side effect supplemental oxygen suppress Symptom T cells the WHO therapeutic Treatment treatment approaches WHO World Health Organization [DOI] 10.1186/s43088-021-00165-0 PMC 바로가기 [Article Type] Review
470. Relapsing COVID-19 Pneumonia in Patients Receiving Rituximab TherapyPoster Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] acute respiratory syndrome administration anti-CD20 Antigen B-cell B-lymphocyte case sery CD20 clinical collected Controlled convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus-2 Corticosteroid Course COVID-19 COVID-19 diagnosis COVID-19 disease death discharge disease disease severity evaluate figure hospital IgG Infection initial management median median age monoclonal antibody Patient patient population patients positive Prevent receive receiving relapsing Remdesivir reported Result retrospective risk rituximab SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV2 severe COVID-19 severity of COVID-19 table therapy virus while [DOI] 10.1093/ofid/ofab466.669 PMC 바로가기 [Article Type] Poster Abstracts
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial성인 외래 환자의 covid-19 치료를 위한 흡입 및 비강 ciclesonide: CONTAIN 2상 무작위 대조 시험Clinical Trial Published on 2021-11-022022-09-11 Journal: The BMJ [Category] 임상, [키워드] 95% confidence interval adjusted adult outpatient adult outpatients assigned benefit Chain Reaction Ciclesonide Combination Comorbidities conducted control group Corticosteroid Corticosteroids cough determine dose double blind Dyspnoea Evidence Fever Follow-up increase in Inhaled interquartile range intervention group intranasal median age modified intention-to-treat nasal not differ Older outcome participant Placebo placebo controlled trial polymerase chain polymerase chain reaction presenting Primary outcome proportion randomisation randomised randomised controlled trial Randomly receive Research resolution of symptom respiratory symptom respiratory symptoms Result risk risk difference saline placebo Sex significantly statistically significant stratified study drug symptom resolution treat treatment of COVID-19 Trial women [DOI] 10.1136/bmj-2021-068060 PMC 바로가기 [Article Type] Clinical Trial
Persistent intrathecal interleukin-8 production in a patient with SARS-CoV-2-related encephalopathy presenting aphasia: a case report.Case Report Published on 2021-11-022022-10-27 Journal: BMC Neurology [Category] COVID-19, [키워드] Aphasia Brain Case report Central nervous system cerebrospinal fluid characteristic Clinical course coronavirus disease Corticosteroid COVID-19 CSF cytokine profile demonstrated Dexamethasone direct infection Encephalopathy IL-10 IL-2 IL-6 IL-8 Immunotherapy include increasingly Inflammation Intravenous immunoglobulin manifestation MCP-1 Methylprednisolone monitoring monocyte chemoattractant protein-1 much higher Neurological deficit occur Patient persistent presenting pulse remained Remdesivir required SARS-CoV-2 SARS-COV-2 infection Seizure serum supplementary material systemic inflammation Treatment [DOI] 10.1186/s12883-021-02459-3 PMC 바로가기 [Article Type] Case Report
Persistent intrathecal interleukin-8 production in a patient with SARS-CoV-2-related encephalopathy presenting aphasia: a case report.Case Report Published on 2021-11-022022-10-27 Journal: BMC Neurology [Category] Coronavirus, COVID-19, MERS, SARS, [키워드] Aphasia Brain Case report Central nervous system cerebrospinal fluid characteristic Clinical course coronavirus disease Corticosteroid COVID-19 CSF cytokine profile demonstrated Dexamethasone direct infection Encephalopathy IL-10 IL-2 IL-6 IL-8 Immunotherapy include increasingly Inflammation Intravenous immunoglobulin manifestation MCP-1 Methylprednisolone monitoring monocyte chemoattractant protein-1 much higher Neurological deficit occur Patient persistent presenting pulse remained Remdesivir required SARS-CoV-2 SARS-COV-2 infection Seizure serum supplementary material systemic inflammation Treatment [DOI] 10.1186/s12883-021-02459-3 PMC 바로가기 [Article Type] Case Report
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial중증 코로나19 폐렴으로 입원한 환자를 대상으로 한 토실리주맙과 렘데시비르: 무작위 임상시험Randomized Controlled Trial Published on 2021-11-012022-09-11 Journal: Intensive care medicine [Category] 임상, 진단, 치료제, [키워드] 7-category ordinal scale 95% CI adverse event assigned benefit clinical status Combination Corticosteroid Corticosteroids COVID-19 COVID-19 pneumonia Cox proportional hazard defined demonstrated died double-blind enrolled evaluated greater hospital discharge hospitalized patient intravenously investigator median time Multicenter trial occurred Ordinal Scale other treatment other treatments oxygen Patient patients patients hospitalized Placebo placebo-controlled Pneumonia Primary outcome provide randomization Randomized randomized clinical trial Randomly receive Remdesivir Serious Adverse Events severe COVID-19 Severe COVID-19 pneumonia supplemental oxygen Tocilizumab Trial [DOI] 10.1007/s00134-021-06507-x PMC 바로가기 [Article Type] Randomized Controlled Trial
Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational studyObservational Study Published on 2021-11-012022-10-05 Journal: Mycoses [Category] 임상, [키워드] Affect Amphotericin analysed Bacterial clinical manifestations Co-infection Combination Complication Corticosteroid COVID COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients Diabetes Mellitus Diabetic diagnosed Diagnosis dominant Frequency Fungal infection fungal infections high risk hospital hospitalisation hypertension Imam Immunocompromised patients incidence Increased Infection Iran Kermanshah laboratory characteristics life-threatening medical record Mucormycosis overall mortality parameter Patient patients with COVID-19 performed physician Prognosis reported Risk factors SARS-CoV-2 surgical Symptom the disease the patient therapeutic therapy Treatment was used [DOI] 10.1111/myc.13351 PMC 바로가기 [Article Type] Observational Study
Exacerbation of immune thrombocytopenia following COVID-19 vaccination코로나19 백신 접종 후 면역 혈소판 감소증 악화Article Published on 2021-11-012022-09-12 Journal: British Journal of Haematology [Category] MERS, 진단, [키워드] Affect bleeding clinical symptom Corticosteroid COVID-19 COVID-19 vaccination Exacerbation had no immune Immune thrombocytopenia Intravenous immunoglobulin median occurred Patient patients Platelet post vaccination rescue Safety Symptom therapy Treatment vaccination Vaccine vaccine dose worsening [DOI] 10.1111/bjh.17645 PMC 바로가기 [Article Type] Article